Camurus ABCAMRF 83 Cash Ratio is 9.72 as of Mar. 2026, which is 209% above its 10-year median of 3.15. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $83.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, Camurus AB ranks better than 79.26% on this metric.
Camurus AB has a Cash Ratio of 9.72. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Camurus AB's Cash Ratio or its related term are showing as below:
CAMRF'
s Cash Ratio Range Over the Past 10 Years
Min: 1.2 Med: 3.15 Max: 10.15
Current: 9.72
During the past 13 years, Camurus AB's highest Cash Ratio was 10.15. The lowest was 1.20. And the median was 3.15.
CAMRF's Cash Ratio is ranked better than 79.26% of 1384
companies
in the Biotechnology industry
Industry Median: 2.955
vs CAMRF: 9.72
Camurus AB (OTCPK:CAMRF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Camurus AB Cash Ratio Related Terms
Camurus AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Cash Ratio of 9.72 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Camurus AB and its competitors. This is 209% above median its historical median of 3.15. Over the past decade, Camurus AB's Cash Ratio has ranged from 1.20 to 10.15. According to the industry distribution chart, Camurus AB ranks #287 out of 1384 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Camurus AB's Cash Ratio too high?
Camurus AB's current Cash Ratio of 9.72 is 209% above median its 10-year median of 3.15. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 10.15. The Biotechnology industry median Cash Ratio is 2.96. Camurus AB's value of 9.72 is 228.9% above this industry median. Based on the distribution chart, Camurus AB ranks #287 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #287 out of 1384 companies for Cash Ratio. This places Camurus AB in the top 21% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.96. Camurus AB's value of 9.72 is 228.9% above this benchmark. Historically, Camurus AB's own Cash Ratio has ranged from 1.20 to 10.15 over the past decade. While the company's 10-year median is 3.15 vs. the industry median of 2.96, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Cash Ratio of 9.72 is 228.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Cash Ratio is 9.72, which is 209% above median its own 10-year median of 3.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.37, compared to a current price of $60.00 — trading 28% below its estimated fair value. The current Cash Ratio is 9.72, which is 209% above median its 10-year median of 3.15 and 228.9% above the Biotechnology industry median of 2.96. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Cash Ratio is 9.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $60.00 is trading 28% below its estimated GF Value™ of $83.37.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Cash Ratio: 9.72 (209% above median its 10-year median of 3.15)
GF Value™: $83.37 vs. price of $60.00 (28% below fair value)
Industry Position: 228.9% above the Biotechnology median (#287 of 1384)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score
Get the complete analysis for CAMRF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
